Wednesday, July 11, 2018

Found a tick on you and want it tested for disease? TestMyTick

A new company started by an Oklahoma dermatologist.

Tulsa Dermatologist Creates Test My Tick Kit
TestMyTick.com
About Us

We've partnered with the preeminent Laboratory of Medical Zoology (LMZ), to offer a battery of tests to detect disease-causing microbes in ticks.  Your tick can be tested for over 20 different disease causing organisms that ticks can carry (like Lyme disease, Rocky Mountain Spotted Fever, and newly discovered diseases like Powassan, Heartland, and Colorado Tick Fever Virus). We now share that data as part of Tick-Borne Disease Network passive surveillance that we hope will provide unprecedented insights to who is being bitten by ticks, when they get bitten, and what pathogens those ticks are carrying. We encourage everyone to SAVE THE TICKS! ....for Testing!

LMZ-   

Laboratory of Medical Zoology (LMZ)
Fernald Hall, University of Massachusetts
Amherst, MA 01003

http://www.tickdiseases.org/



Unusually High Levels of HHV Found in the Brains of Those With Alzheimer's

Unusually High Levels of HHV Found in the Brains of Those With Alzheimer's


Tuesday, July 10, 2018

WSJ Article- New Effort for Lyme Disease Vaccine Draws Early Fire

Requires a subscription to Wall Street Journal. Sorry.

New Effort for Lyme Disease Vaccine Draws Early Fire
 
By 
Sumathi Reddy
Updated July 9, 2018 3:48 p.m. ET

Efforts to bring a vaccine for Lyme disease to the market have run aground amid heated debate over the years.

Now, a European company is in the early stages of creating a vaccine for the increasingly common tick-borne disease. Lyme disease patient-advocacy groups—who disagree with the protocols used by most doctors for the diagnosis andtreatment of Lyme disease—are already raising concerns.
 

Saturday, July 7, 2018

Study of NLY01 at Hopkins: Stops Parkinson's disease progression

July 7, 2018 

Experimental Drug Halts Parkinson's Progression, Study Says; Johns Hopkins University researchers

·          
·          

An experimental drug developed by Johns Hopkins University researchers appears to slow down the progression of Parkinson's disease and its symptoms in mice, 

The researchers said that the drug called NLY01 has been proven in studies to block the degradation of brain cells that is the leading cause of Parkinson's disease. The treatment has been used in the past to treat diabetes, researchers said in the university statement.

The study's results, which were published last month in the journal Nature Medicine, reported that NLY01 works by binding to glucagon-like peptide-1 receptors on the surface of certain cells. Similar drugs are used widely in the treatment of type 2 diabetes to increase insulin levels in the blood, the university statement said.

"NLY01 also prolongs the life and reduces the behavioral deficits and neuropathological abnormalities in the human A53T α-synuclein (hA53T) transgenic mouse model of α-synucleinopathy-induced neurodegeneration," 

Parkinson's disease is a progressive disorder of the nervous system that affects about 1 million people in the United States and 10 million worldwide, 

"It is amazingly protective of target nerve cells," Ted Dawson, director of the Institute for Cell Engineering at the Johns Hopkins University School of Medicine, said in the university's statement.

The drug is expected to move to clinical trials later this year, the statement said. Dawson added that if planned clinical trials are successful in humans, it could be one of the first treatments to directly target the progression of Parkinson's disease, not just the muscle rigidity, spasmodic movements, fatigue, dizziness, dementia, and other symptoms of the disorder.

Dawson cautioned that NLY01 must still be tested for safety as well as effectiveness in people but based on the safety profile of other similar drugs, he does not anticipate any major hurdles on the way to human trials.

The researcher added that they are hopeful that NLY01 could, in a relatively short period of time, make an impact on the lives of those with Parkinson's, the university statement said.

Friday, July 6, 2018

Eco researchers discuss Lyme

Experts Discuss Research Into Lyme And Tick-Borne Diseases

The Cary Institute of Ecosystem Studies recently co-hosted a panel discussion on the subject, where experts talked about the ongoing research. 

Tuesday, July 3, 2018

Press release about a vaccine against Lyme disease

Press Release:

VALNEVA Announces Significant Progress of its Lyme Disease Vaccine Candidate

The Company has successfully concluded the end of Phase 1 process for this candidate with the Food and Drug Administration (FDA) and has obtained alignment with regard to its Phase 2 strategy.

Valneva is now finalizing the detailed Phase 2 protocol and, subject to requisite regulatory approvals, expects to enter Phase 2 clinical development by the end of 2018.

Thursday, May 31, 2018

Blood banks still accepting blood from Lyme patients


 . . . a Lyme Disease patient in Arkansas is raising awareness about the fact that she, and other Lyme Disease patients, can still give blood.

According to the CDC, Lyme disease is one of the fastest-growing infectious diseases in the United States. The CDC also reports that Lyme disease can live in blood that is stored for donation.

Even still, patients in Arkansas say they can still donate blood, despite the risk of passing it to others. 

Saturday, May 19, 2018

More Lyme workingroup updates

Two more meetings of Working Group; New Lyme legislation introduced in Congress
This was a big week for the Lyme community in Washington DC.

First off, the Tick-Borne Disease Working Group met for two day-long sessions. Read our summaries here:



Then, on Friday, May 18, Congressman Chris Smith of New Jersey introduced the National Lyme and Tick-Borne Diseases Control and Accountability Act of 2018. Read more here.